Title : Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.

Pub. Date : 2008

PMID : 18436994






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). Phenylalanine ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens